No Clinically Significant Drug Interactions Between Zepbound and Dupixent
There are no documented drug-drug interactions between Zepbound (tirzepatide) and Dupixent (dupilumab), and these medications can be safely used together.
Mechanistic Rationale
Dupixent's Interaction Profile
Dupixent (dupilumab) is a monoclonal antibody that blocks IL-4 and IL-13 signaling. The FDA label explicitly states that "an effect of dupilumab on the PK of co-administered medications is not expected" 1. This has been confirmed through formal drug interaction studies showing dupilumab does not affect cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2) 1, 2.
- Dupixent is a large protein molecule (monoclonal antibody) that undergoes minimal metabolism and is not processed through hepatic enzyme systems
- Research confirms that blockade of IL-4/IL-13 signaling does not significantly affect CYP450 enzyme activities 2
- Dupixent does not exert immunosuppressive effects that would interact with other biologics 3
Tirzepatide's Interaction Profile
Tirzepatide is a peptide-based dual GLP-1/GIP receptor agonist with structural modifications (amino acid substitutions and fatty acid conjugation) that result in minimal metabolism and renal excretion 4.
- No clinically significant drug-metabolizing enzyme or transporter-mediated interactions have been reported 4
- The primary interaction concern with tirzepatide involves delayed gastric emptying affecting oral medication absorption 4
- This gastric emptying effect is irrelevant for Dupixent, which is administered subcutaneously
Clinical Evidence for Safety
Small case series have documented safe combination of dupilumab with other monoclonal antibodies for various conditions, with no adverse events related to the combination except mild injection site reactions 3. While this specific evidence doesn't include tirzepatide, it demonstrates dupilumab's benign interaction profile with other biologics.
Important Caveats
Monitor for Individual Medication Side Effects
While no interaction exists, both medications have their own adverse effect profiles that require monitoring:
For Tirzepatide:
- Gastrointestinal effects (nausea, vomiting)
- Hypoglycemia risk if used with insulin or sulfonylureas
- Injection site reactions
- Dosing errors are common in real-world use 5
For Dupixent:
- Conjunctivitis (most common: 2-8% depending on indication) 1
- Injection site reactions
- Eosinophilia (typically transient and asymptomatic) 1
No Dose Adjustments Required
Neither medication requires dose adjustment when used together, as they operate through completely independent mechanisms and metabolic pathways.